Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + irinotecan liposome maintenance after first-line adebrelimab + chemotherapy in extensive-stage small cell lung cancer
ChiCTR2500108502Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in small cell lung cancer (SCLC), sponsored by Hunan Cancer Hospital. Primary endpoint: 6-month progression-free survival rate. Started Sep 2025; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500108502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108502.